End-of-day quote
Korea S.E.
03:30:00 31/05/2024 am IST
|
5-day change
|
1st Jan Change
|
37,500
KRW
|
-6.95%
|
|
-3.10%
|
+226.09%
|
Fiscal Period: December |
2023
|
---|
Capitalization
1 |
1,30,376
|
Enterprise Value (EV)
1 |
1,31,714
|
P/E ratio
|
-16.7
x
|
Yield
|
-
|
Capitalization / Revenue
|
9.95
x
|
EV / Revenue
|
10
x
|
EV / EBITDA
|
-29.7
x
|
EV / FCF
|
-16.5
x
|
FCF Yield
|
-6.05%
|
Price to Book
|
18.8
x
|
Nbr of stocks (in thousands)
|
11,337
|
Reference price
2 |
11,500
|
Announcement Date
|
21/03/24
|
Fiscal Period: December |
2023
|
---|
Net sales
1 |
13,108
|
EBITDA
1 |
-4,436
|
EBIT
1 |
-5,989
|
Operating Margin
|
-45.69%
|
Earnings before Tax (EBT)
1 |
-6,337
|
Net income
1 |
-7,524
|
Net margin
|
-57.39%
|
EPS
2 |
-688.2
|
Free Cash Flow
1 |
-7,972
|
FCF margin
|
-60.82%
|
FCF Conversion (EBITDA)
|
-
|
FCF Conversion (Net income)
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
21/03/24
|
Fiscal Period: December |
2023
|
---|
Net Debt
1 |
1,337
|
Net Cash position
1 |
-
|
Leverage (Debt/EBITDA)
|
-0.3015
x
|
Free Cash Flow
1 |
-7,972
|
ROE (net income / shareholders' equity)
|
-97.1%
|
ROA (Net income/ Total Assets)
|
-13.3%
|
Assets
1 |
56,585
|
Book Value Per Share
2 |
611.0
|
Cash Flow per Share
2 |
124.0
|
Capex
1 |
1,847
|
Capex / Sales
|
14.09%
|
Announcement Date
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +226.09% | 310M | | -1.85% | 89.87B | | -3.95% | 37.57B | | +62.67% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +5.17% | 9.11B | | -19.53% | 7.32B |
Biopharmaceuticals
|